Outsourced Pharma Capacity Update Videos - Large Molecule

  1. Resilience Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    Business Head of Biologics and Vaccines Evan Pasenello shares how Resilience’s innovative platforms and specialized expertise can effectively support your development and manufacturing programs.

  2. Boehringer Ingelheim BioXcellence™ Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    Explore our global production network, advanced aseptic filling, in-house analytics, and the expertise that has driven 47 biopharmaceuticals to market success.

  3. FUJIFILM Diosynth Biotechnologies Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    Rasmus Pedersen, Ph.D., outlines strategies to expand large-molecule production capacity to meet the global medicine demand, noting the current gap that leaves 2 billion people without access.

  4. Samsung Biologics Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    We're poised to be your next growth engine with our commitment to quality, speed, and agility, as we expand our facilities and invest in innovative modalities to meet your large molecule needs.

  5. Cytovance Capacity Update July 2024: Large Molecule Development 9/18/2024

    Centrally located in the United States, with a decades-long history in biologics development and manufacturing, Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.

  6. ATON Bio Capacity Update July 2024: Large Molecule Development 8/14/2024

    Gain insights into boosting efficiency, fostering innovation, and how integrated capabilities generate value for innovators.

  7. Curia Capacity Update July 2024: Large Molecule Development 8/14/2024

    Curia Biologics can be a critical partner for small, midsize, and even large biotech businesses to support all requirements from IND through late stage commercial programs.

  8. Mabion Capacity Update July 2024: Large Molecule Development 8/14/2024

    Explore our new installations in upstream development, bioreactors, and fill-finish. This state of the art EU-GMP facility is staffed by a team of 250 professionals, and capacity is now available.

  9. Novartis Contract Manufacturing Capacity Update July 2024: Large Molecule Development 8/14/2024

    Review our capabilities in tech transfer, clinical drug substance, and commercial drug substance manufacturing across our manufacturing network in Singapore, Europe, and the US.

  10. AbbVie Capacity Update July 2024: Large Molecule Development 8/14/2024

    Delve into the intricacies of biopharmaceutical manufacturing, focusing on stages such as CLD, fermentation, and purification. We also explore process optimization and scale-up techniques.